How does Johnson & Johnson (JNJ) make money?

Johnson & Johnson (JNJ) generates revenue primarily from Innovative Medicine, which accounted for 64.3% of total revenue in TTM through Q2 2026. The company reported $99.2B in revenue and converted 21.6% of it into net profit, equivalent to roughly $21.4B in net income — what's left after the cost of revenue, operating expenses, interest, and income taxes.

What is the gross profit margin of Johnson & Johnson (JNJ)?

Johnson & Johnson (JNJ) reported a gross profit margin of 71.3% in TTM through Q2 2026, equivalent to $70.8B in gross profit on $99.2B in revenue. Gross margin measures how much of each dollar of revenue remains after the direct cost of producing or delivering the product — a higher figure typically signals pricing power, scale, or a less capital-intensive business model.

What is the operating profit margin of Johnson & Johnson (JNJ)?

Johnson & Johnson (JNJ) reported an operating profit margin of 26.5% in TTM through Q2 2026, equivalent to $26.3B in operating income. Operating margin captures profitability after research & development, sales & marketing, and general & administrative expenses — but before interest, taxes, and one-off items — and is the cleanest single read on the underlying business's efficiency.

What is the net profit margin of Johnson & Johnson (JNJ)?

Johnson & Johnson (JNJ) reported a net profit margin of 21.6% in TTM through Q2 2026, equivalent to $21.4B in net income. Net margin is the bottom-line share of revenue that survives every expense — operating costs, interest, and income taxes — and is the figure that flows directly into earnings per share.

Is Johnson & Johnson (JNJ) profitable?

Yes. Johnson & Johnson (JNJ) reported $21.4B in net income for TTM through Q2 2026, with a net profit margin of 21.6%. The company earned more from its operations than it paid out in costs, interest, and income taxes, leaving positive earnings on the bottom line.

How much does Johnson & Johnson (JNJ) invest in research and development?

Johnson & Johnson (JNJ) invested $15.1B in research and development during TTM through Q2 2026, roughly 15.2% of total revenue. R&D spending funds the company's future product pipeline and is expensed in full on the income statement rather than capitalised, which makes the operating margin sensitive to how aggressively management chooses to reinvest in innovation.

How much does Johnson & Johnson (JNJ) spend on capital expenditures?

Johnson & Johnson (JNJ) spent $5B on capital expenditures (CapEx) during TTM through Q2 2026, roughly 5.0% of total revenue. CapEx represents long-lived investment in property, equipment, data centres, and other physical infrastructure, and is subtracted from operating cash flow to arrive at free cash flow.

How much free cash flow does Johnson & Johnson (JNJ) generate?

Johnson & Johnson (JNJ) generated $18.7B in free cash flow during TTM through Q2 2026, a free-cash-flow margin of 18.9%. Free cash flow is the cash left after capital expenditures and represents the discretionary pool the company can use to pay dividends, repurchase shares, repay debt, or fund acquisitions without raising external capital.

What is the effective tax rate of Johnson & Johnson (JNJ)?

Johnson & Johnson (JNJ) had an effective tax rate of 12.4% in TTM through Q2 2026. The effective rate is the actual share of pre-tax income paid as income taxes and can differ materially from the statutory rate due to foreign earnings mix, tax credits (such as R&D), share-based compensation deductions, and one-off discrete items.

What are the main business segments of Johnson & Johnson (JNJ)?

Johnson & Johnson (JNJ) reports revenue across 2 reportable product segments, led by Innovative Medicine at 64.3% of total revenue in TTM through Q2 2026. See the revenue-by-segment table on this page for the full breakdown and how each segment feeds into the income-statement waterfall above.

Where does Johnson & Johnson (JNJ) generate most of its revenue?

UNITED STATES is the largest geographic market for Johnson & Johnson (JNJ), accounting for 39.8% of revenue in the most recent annual filing. The complete regional split — including international markets and any Rest-of-World rollup — is shown in the revenue-by-geography table on this page.

How Johnson & Johnson Makes Money: 2026 Visual Revenue Map

Johnson & Johnson (JNJ) Income Statement Flow — TTM through Q2 2026

Calculated from the four most recent reported quarters, ending June 30, 2026 (reported June 30, 2026).

Johnson & Johnson (JNJ) Revenue by Product Segment — TTM through Q2 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported segments changed mid-year.

Revenue contribution by product segment for Johnson & Johnson (JNJ), TTM through Q2 2026.
Segment	Revenue (USD)	% of total
Innovative Medicine	$63.9B	64.3%
MedTech	$35.4B	35.7%
Total	$99.2B	100%

Innovative Medicine$63.9B
MedTech$35.4B
Total$99.2B

Johnson & Johnson (JNJ) Revenue by Geography — TTM through Q2 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported regions changed mid-year.

Revenue contribution by geographic region for Johnson & Johnson (JNJ), TTM through Q2 2026
Region	Revenue (USD)	% of total
UNITED STATES	$27.9B	39.8%
Europe	$22.6B	32.3%
Asia-Pacific, Africa	$14.4B	20.6%
Western Hemisphere, excluding U.S.	$5.1B	7.3%
Total	$70.1B	100%

UNITED STATES
Europe
Asia-Pacific, Africa
Western Hemisphere, excluding U.S.
Total

Revenue Breakdown — TTM through Q2 2026

In TTM through Q2 2026, Johnson & Johnson (JNJ) reports revenue across 2 reportable product segments; the largest segment was Innovative Medicine at 64.3%, followed by MedTech (35.7%). Geographically, UNITED STATES accounted for 39.8% of revenue, followed by Europe (32.3%) and Asia-Pacific, Africa (20.6%).

Frequently asked questions

Data & methodology

Johnson & Johnson (JNJ) Key Financials

Charts, filings, and peer comparison for every metric

Trains Company Knowledge

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview

JNJ Overview

Counters

Income Statement

Cash Flow

Capital Return

How this company returns cash to shareholders — buybacks, dividends, and stock splits.

Forecast & Valuation